Hudson Bay Capital Management
CPRX icon

Hudson Bay Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hudson Bay Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-280,000
Closed -$4.46M – 806
2024
Q1 		$4.46M Buy
280,000
+120,000
+75% +$1.81M 0.02% 323
2023
Q4 		$2.69M Sell
160,000
-140,000
-47% -$1.91M 0.02% 404
2023
Q3 		$3.51M Buy
300,000
+100,000
+50% +$1.34M 0.03% 375
2023
Q2 		$2.69M Buy
+200,000
New +$2.88M 0.02% 449

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Hudson Bay Capital Management's CPRX Position: Q2 2024 in Review

Hudson Bay Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 280,000 shares — an estimated $4.46M sold.

Hudson Bay Capital Management first reported a position in CPRX in Q2 2023 and held it in 4 quarters. The position peaked at $4.46M in Q1 2024. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

  • Hudson Bay Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 280,000 Catalyst Pharmaceutical shares in Q2 2024, an estimated $4.46M.
  • Hudson Bay Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 4 quarters.
  • Hudson Bay Capital Management's Catalyst Pharmaceutical position peaked at $4.46M in Q1 2024.
  • 271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Hudson Bay Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.